

**KADCYLA Vials 160 mg**Version  
1.0Revision Date:  
07/28/2025Date of last issue: -  
Date of first issue: 07/28/2025**SECTION 1. IDENTIFICATION**

Product name : KADCYLA Vials 160 mg

Product code : RO530-4020/F02-00

Common name(s),  
synonym(s) of the substance : KADCYLA Lyophilized Vials**Manufacturer or supplier's details**

Company name of supplier : Genentech, Inc.

Address : 1 DNA Way  
South San Francisco, CA 94080  
USA

Telephone : 001-(650) 225-1000

E-mail address : info.sds@roche.com

Emergency telephone

In case of emergencies: : US CHEMTREC PHONE (800)-424-9300

**Recommended use of the chemical and restrictions on use**

Recommended use : Formulated pharmaceutical active substance

---

**SECTION 2. HAZARDS IDENTIFICATION****GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)**

Combustible dust

Acute toxicity (Oral) : Category 3

Acute toxicity (Inhalation) : Category 4

Germ cell mutagenicity : Category 1B

Reproductive toxicity : Category 1B

**GHS label elements**

Hazard pictograms :



Signal Word : Danger

Hazard Statements : May form combustible dust concentrations in air.

H301 Toxic if swallowed.

H332 Harmful if inhaled.

H340 May cause genetic defects.

H360FD May damage fertility. May damage the unborn child.

**KADCYLA Vials 160 mg**Version  
1.0Revision Date:  
07/28/2025Date of last issue: -  
Date of first issue: 07/28/2025**Precautionary Statements****Prevention:**

P201 Obtain special instructions before use.  
P202 Do not handle until all safety precautions have been read and understood.  
P261 Avoid breathing dust.  
P264 Wash skin thoroughly after handling.  
P270 Do not eat, drink or smoke when using this product.  
P271 Use only outdoors or in a well-ventilated area.  
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

**Response:**

P301 + P310 + P330 IF SWALLOWED: Immediately call a POISON CENTER/ doctor. Rinse mouth.  
P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/ doctor if you feel unwell.  
P308 + P313 IF exposed or concerned: Get medical advice/ attention.

**Storage:**

P405 Store locked up.

**Disposal:**

P501 Dispose of contents/ container to an approved waste disposal plant.

**Other hazards**

None known.

---

**SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

**Components**

Chemical name	CAS-No.	Concentration (% w/w)
Trastuzumab emtansine	1018448-65-1	24.4
.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl	57-50-1	73.4
Butanedioic acid, sodium salt (1:2)	150-90-3	2
Sorbitan, monododecanoate, poly(oxy-1,2-ethanediyl) derivs.	9005-64-5	0.2

---

**SECTION 4. FIRST AID MEASURES**

General advice : Move out of dangerous area.  
Consult a physician.  
Show this material safety data sheet to the doctor in attendance.  
Symptoms of poisoning may appear several hours later.

**KADCYLA Vials 160 mg**
Version  
1.0Revision Date:  
07/28/2025Date of last issue: -  
Date of first issue: 07/28/2025

If inhaled : Do not leave the victim unattended.  
 Consult a physician after significant exposure.  
 If unconscious, place in recovery position and seek medical advice.

In case of skin contact : Wash off with soap and water.

In case of eye contact : Flush eyes with water as a precaution.  
 Remove contact lenses.  
 Protect unharmed eye.  
 Keep eye wide open while rinsing.  
 If eye irritation persists, consult a specialist.

If swallowed : Induce vomiting immediately and call a physician.  
 Keep respiratory tract clear.  
 Do not give milk or alcoholic beverages.  
 Never give anything by mouth to an unconscious person.  
 If symptoms persist, call a physician.  
 Take victim immediately to hospital.

Most important symptoms and effects, both acute and delayed : Toxic if swallowed.  
 Harmful if inhaled.  
 May cause genetic defects.  
 May damage fertility. May damage the unborn child.

Protection of first-aiders : First Aid responders should pay attention to self-protection and use the recommended protective clothing

Notes to physician : Treat symptomatically.

---

**SECTION 5. FIRE-FIGHTING MEASURES**

Suitable extinguishing media : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

Unsuitable extinguishing media : High volume water jet

Specific hazards during fire fighting : Do not allow run-off from fire fighting to enter drains or water courses.

Hazardous combustion products : Carbon oxides  
 Nitrogen oxides (NOx)

Further information : Collect contaminated fire extinguishing water separately. This must not be discharged into drains.  
 Fire residues and contaminated fire extinguishing water must be disposed of in accordance with local regulations.

Special protective equipment : Wear self-contained breathing apparatus for firefighting if

**KADCYLA Vials 160 mg**Version  
1.0Revision Date:  
07/28/2025Date of last issue: -  
Date of first issue: 07/28/2025

for fire-fighters

necessary.

**SECTION 6. ACCIDENTAL RELEASE MEASURES**

Personal precautions, protective equipment and emergency procedures : Prevent any exposure  
Use personal protective equipment.  
Avoid dust formation.  
Avoid breathing dust.  
Ensure adequate ventilation.  
Refer to protective measures listed in sections 7 and 8.

Environmental precautions : Prevent product from entering drains.  
Prevent further leakage or spillage if safe to do so.  
If the product contaminates rivers and lakes or drains inform respective authorities.

Methods and materials for containment and cleaning up : Wash contaminated surfaces with sodium hydroxide solution,  $c(\text{NaOH})=0.5 \text{ mol/L}$  to 1 mol/L, and rinse with water  
  
Keep in suitable, closed containers for disposal.

**SECTION 7. HANDLING AND STORAGE**

Advice on protection against fire and explosion : Avoid dust formation.  
Provide appropriate exhaust ventilation at places where dust is formed.

Advice on safe handling : Avoid formation of respirable particles.  
Do not breathe vapors/dust.  
Avoid exposure - obtain special instructions before use.  
Avoid contact with skin and eyes.  
For personal protection see section 8.  
Smoking, eating and drinking should be prohibited in the application area.  
Provide sufficient air exchange and/or exhaust in work rooms.  
Dispose of rinse water in accordance with local and national regulations.

Conditions for safe storage : Prevent unauthorized access.  
Keep container tightly closed in a dry and well-ventilated place.  
Containers which are opened must be carefully resealed and kept upright to prevent leakage.  
Electrical installations / working materials must comply with the technological safety standards.

Storage temperature : Protect from moisture.  
Protect from heat and light

Further information on : Keep in a dry place.

**KADCYLA Vials 160 mg**
Version  
1.0Revision Date:  
07/28/2025Date of last issue: -  
Date of first issue: 07/28/2025

storage stability No decomposition if stored and applied as directed.

Packaging material : Suitable material: Vials, glass, Stainless steel

---

**SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION**
**Ingredients with workplace control parameters**

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl	57-50-1	TWA	10 mg/m3	ACGIH
		TWA (Respirable)	5 mg/m3	NIOSH REL
		TWA (total)	10 mg/m3	NIOSH REL
		TWA (total dust)	15 mg/m3	OSHA Z-1
		TWA (respirable fraction)	5 mg/m3	OSHA Z-1
		TWA (Total dust)	15 mg/m3	OSHA P0
		TWA (respirable dust fraction)	5 mg/m3	OSHA P0
Trastuzumab emtansine	1018448-65-1	IOEL	0.0003 mg/m3	Roche Industrial Hygiene Committee (RIHC)

**Personal protective equipment**

Respiratory protection : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

**Hand protection**

Material : Nitrile rubber  
Break through time : > 30 min  
Glove thickness : > 0.11 mm

Material : In case of full contact:  
butyl-rubber

**KADCYLA Vials 160 mg**Version  
1.0Revision Date:  
07/28/2025Date of last issue: -  
Date of first issue: 07/28/2025

Break through time : > 480 min  
Glove thickness : > 0.4 mm

Remarks : Wear appropriate protective gloves to prevent skin contact.  
Replace torn or punctured gloves promptly.  
Eye protection : Eye wash bottle with pure water  
Tightly fitting safety goggles  
Skin and body protection : Dust impervious protective suit  
Choose body protection according to the amount and  
concentration of the dangerous substance at the work place.  
Protective measures : Instruction of employees mandatory  
Hygiene measures : Avoid contact with skin, eyes and clothing.  
When using do not eat or drink.  
When using do not smoke.  
Wash hands before breaks and immediately after handling  
the product.

---

**SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

Appearance : powder, sterile, (lyophilized)

Color : off-white

Odor : Not applicable

Odor Threshold : Not applicable

pH : Not applicable

Melting point/ range : No data available

Boiling point/boiling range : No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : No data available

Self-ignition : No data available

Upper explosion limit / Upper  
flammability limit : No data available

Lower explosion limit / Lower : No data available

**KADCYLA Vials 160 mg**Version  
1.0Revision Date:  
07/28/2025Date of last issue: -  
Date of first issue: 07/28/2025

flammability limit

Vapor pressure : No data available

Relative vapor density : Not applicable

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : soluble

Solubility in other solvents : No data available

Partition coefficient: n-octanol/water : No data available

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, dynamic : Not applicable

Viscosity, kinematic : Not applicable

Explosive properties : No data available

Oxidizing properties : No data available

Particle characteristics

Particle Size Distribution : No data available

---

**SECTION 10. STABILITY AND REACTIVITY**

Reactivity : No dangerous reaction known under conditions of normal use.

Chemical stability : Stable under normal conditions.

Proteins are temperature-sensitive; the thermal denaturation has an impact on quality but does not affect Plant and Process Safety; during decomposition no flammable gas, no organic peroxide and no oxidising substances are created

Possibility of hazardous reactions : No decomposition if stored and applied as directed. Dust may form explosive mixture in air.

Conditions to avoid : No data available

Incompatible materials : Not applicable

Hazardous decomposition products : No hazardous decomposition products are known.

**KADCYLA Vials 160 mg**Version  
1.0Revision Date:  
07/28/2025Date of last issue: -  
Date of first issue: 07/28/2025**SECTION 11. TOXICOLOGICAL INFORMATION****Acute toxicity**

Toxic if swallowed.  
Harmful if inhaled.

**Product:**

Acute oral toxicity : Acute toxicity estimate: 113.81 mg/kg  
Method: Expert judgment

Acute inhalation toxicity : Acute toxicity estimate: 1.14 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Method: Expert judgment

**Components:****.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**

Acute oral toxicity : LD50 Oral (Rat): 29,700 mg/kg

**Trastuzumab emtansine:**

Acute oral toxicity : Acute toxicity estimate (Mouse): 27.77 mg/kg  
Method: Expert judgment

Acute toxicity estimate (Mouse): 0.5 mg/kg  
Method: OECD Test Guideline 423  
The value is given in analogy to the following substances:  
Ansamitosin P3

Acute inhalation toxicity : Acute toxicity estimate (Rat): 0.277 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Method: Expert judgment

Acute toxicity estimate (Rat): 0.005 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
The value is given in analogy to the following substances:  
Ansamitosin P3

Acute toxicity (other routes of administration) : HNSTD (Highest Non-Severely Toxic Dose) (cynomolgus monkey): 30 mg/kg  
Application Route: i.v.

HNSTD (Highest Non-Severely Toxic Dose) (Rat): 20 mg/kg  
Application Route: i.v.

**Skin corrosion/irritation**

Based on available data, the classification criteria are not met.

**Product:**

**KADCYLA Vials 160 mg**Version  
1.0Revision Date:  
07/28/2025Date of last issue: -  
Date of first issue: 07/28/2025

Assessment : No skin irritation  
Remarks : Expert judgment

**Components:****Trastuzumab emtansine:**

Result : Irritating to skin.  
Remarks : Expert judgment

**Serious eye damage/eye irritation**

Not classified due to lack of data.

**Respiratory or skin sensitization****Skin sensitization**

Not classified due to lack of data.

**Respiratory sensitization**

Not classified due to lack of data.

**Germ cell mutagenicity**

May cause genetic defects.

**Product:**

Germ cell mutagenicity - : In vivo tests showed mutagenic effects  
Assessment

**Components:****.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test  
Result: negative

**Trastuzumab emtansine:**

Genotoxicity in vitro : Method: OECD Test Guideline 471  
Result: negative  
The value is given in analogy to the following substances:  
DM1

Genotoxicity in vivo : Method: Mutagenicity (micronucleus test)  
Result: positive  
The value is given in analogy to the following substances:  
DM1

Germ cell mutagenicity - : In vivo tests showed mutagenic effects  
Assessment

**Carcinogenicity**

Based on available data, the classification criteria are not met.

**Product:**

**KADCYLA Vials 160 mg**
Version  
1.0Revision Date:  
07/28/2025Date of last issue: -  
Date of first issue: 07/28/2025

**Carcinogenicity - Assessment** : Weight of evidence does not support classification as a carcinogen

**Components:****.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**

**Remarks** : No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

**Trastuzumab emtansine:**

**Carcinogenicity - Assessment** : Limited evidence of a carcinogenic effect.

**IARC** No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

**OSHA** No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

**NTP** No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

**Reproductive toxicity**

May damage fertility. May damage the unborn child.

**Product:**

**Reproductive toxicity - Assessment** : Presumed human reproductive toxicant, May damage fertility. May damage the unborn child.

**Components:****Trastuzumab emtansine:**

**Reproductive toxicity - Assessment** : Presumed human reproductive toxicant, May damage fertility. May damage the unborn child.

**STOT-single exposure**

Based on available data, the classification criteria are not met.

**Product:**

**Assessment** : The substance or mixture is not classified as specific target organ toxicant, single exposure.

**Remarks** : Expert judgment

**Components:****.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**

**Assessment** : The substance or mixture is not classified as specific target organ toxicant, single exposure.

**KADCYLA Vials 160 mg**Version  
1.0Revision Date:  
07/28/2025Date of last issue: -  
Date of first issue: 07/28/2025**Trastuzumab emtansine:**

Target Organs : Nervous system, Reproductive organs, Bone marrow  
Assessment : May cause damage to organs.  
Remarks : i.v.

**STOT-repeated exposure**

Based on available data, the classification criteria are not met.

**Product:**

Assessment : The substance or mixture is not classified as specific target organ toxicant, repeated exposure.  
Remarks : Expert judgment

**Components:****.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**

Assessment : The substance or mixture is not classified as specific target organ toxicant, repeated exposure.

**Trastuzumab emtansine:**

Target Organs : Nervous system, Reproductive organs, Bone marrow  
Assessment : May cause damage to organs through prolonged or repeated exposure.  
Remarks : i.v.

**Repeated dose toxicity****Components:****Trastuzumab emtansine:**

Species : cynomolgus monkey  
: 10 mg/kg  
Application Route : i.v.  
Exposure time : 9 Weeks  
Number of exposures : 3  
Remarks : Subacute toxicity

**Aspiration toxicity**

Not classified due to lack of data.

**Components:****.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**

No data available

## KADCYLA Vials 160 mg

Version  
1.0Revision Date:  
07/28/2025Date of last issue: -  
Date of first issue: 07/28/2025**Further information****Product:**

Remarks : No data available

**Components:****.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**

Remarks : Health injuries are not known or expected under normal use.

**Trastuzumab emtansine:**

Remarks : after parenteral application, rare cases of hypersensitivity, including anaphylactic shock, can occur

The value is given in analogy to the following substances: Trastuzumab

---

**SECTION 12. ECOLOGICAL INFORMATION****Ecotoxicity****Components:****.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:****Ecotoxicology Assessment**

Acute aquatic toxicity : This product has no known ecotoxicological effects.

Chronic aquatic toxicity : This product has no known ecotoxicological effects.

Toxicity Data on Soil : Not expected to adsorb on soil.

Other organisms relevant to the environment : No data available

**Trastuzumab emtansine:**Toxicity to fish : LC50 (Poecilia reticulata (guppy)): > 100 mg/l  
Exposure time: 96 h  
Test Type: semi-static test  
Method: OECD Test Guideline 203  
GLP: yes  
Remarks: nominal concentrationNOEC (Poecilia reticulata (guppy)): < 100 mg/l  
Exposure time: 96 h  
Test Type: semi-static test  
Method: OECD Test Guideline 203  
GLP: yes  
Remarks: nominal concentrationToxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l  
End point: Immobilization  
Exposure time: 48 h

## KADCYLA Vials 160 mg

Version  
1.0Revision Date:  
07/28/2025Date of last issue: -  
Date of first issue: 07/28/2025

Method: OECD Test Guideline 202

GLP: yes

Remarks: nominal concentration

NOEC (Daphnia magna (Water flea)): 100 mg/l

End point: Immobilization

Exposure time: 48 h

Method: OECD Test Guideline 202

GLP: yes

Remarks: nominal concentration

Toxicity to algae/aquatic plants : ErC50 (Desmodesmus subspicatus (green algae)): &gt; 100 mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

GLP: yes

Remarks: nominal concentration

EyC50 (Desmodesmus subspicatus (green algae)): ca. 100 mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

GLP: yes

Remarks: nominal concentration

Toxicity to microorganisms : (activated sludge): 49.5 mg/l

Exposure time: 14 d

Test Type: Respiration inhibition

Method: OECD Test Guideline 301F

GLP: yes

Remarks: Barely inhibitory on aerobic bacterial reproduction (activated sludge)

nominal concentration

**Persistence and degradability****Components:****Trastuzumab emtansine:**Biodegradability : Concentration: 1,000 mg/l  
Theoretical oxygen demand  
Result: Not readily biodegradable.  
Biodegradation: 84 %  
Exposure time: 28 d  
Method: OECD Test Guideline 301F  
GLP: yes**Bioaccumulative potential****Components:****.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**

Partition coefficient: n-octanol/water : log Pow: -3.7 (68 °F / 20 °C)

**Trastuzumab emtansine:**

**KADCYLA Vials 160 mg**

Version 1.0 Revision Date: 07/28/2025 Date of last issue: - Date of first issue: 07/28/2025

Partition coefficient: n-octanol/water : Remarks: No data available

**Mobility in soil**

No data available

**Other adverse effects****Product:**

Ozone-Depletion Potential : Regulation: 40 CFR Protection of Environment; Part 82 Protection of Stratospheric Ozone - CAA Section 602 Class I Substances  
Remarks: This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).  
Additional ecological information : No data available

---

**SECTION 13. DISPOSAL CONSIDERATIONS****Disposal methods**

Waste from residues : Do not dispose of waste into sewer.  
Do not contaminate ponds, waterways or ditches with chemical or used container.  
Send to a licensed waste management company.  
Contaminated packaging : Empty remaining contents.  
Dispose of as unused product.  
Do not re-use empty containers.

---

**SECTION 14. TRANSPORT INFORMATION****International Regulations****UNRTDG**

UN number : UN 3249  
Proper shipping name : MEDICINE, SOLID, TOXIC, N.O.S.  
Class : 6.1  
Packing group : III  
Labels : 6.1  
Environmentally hazardous : no

**IATA-DGR**

UN/ID No. : UN 3249  
Proper shipping name : Medicine, solid, toxic, n.o.s.  
Class : 6.1  
Packing group : III  
Labels : Division 6.1 - Toxic substances  
Packing instruction (cargo aircraft) : 677  
Packing instruction (passenger aircraft) : 670

**KADCYLA Vials 160 mg**
Version  
1.0Revision Date:  
07/28/2025Date of last issue: -  
Date of first issue: 07/28/2025**IMDG-Code**

UN number : UN 3249  
 Proper shipping name : MEDICINE, SOLID, TOXIC, N.O.S.

Class : 6.1  
 Packing group : III  
 Labels : 6.1  
 EmS Code : F-A, S-A  
 Marine pollutant : no

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable

**Domestic regulation****49 CFR**

UN/ID/NA number : UN 3249

Proper shipping name : Medicine, solid, toxic, n.o.s.

Class : 6.1  
 Packing group : III  
 Labels : Division 6.1 - Toxic substances  
 ERG Code : 151  
 Marine pollutant : no

**Special precautions for user**

Remarks : No data available

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

---

**SECTION 15. REGULATORY INFORMATION**
**CERCLA Reportable Quantity**

This material does not contain any components with a CERCLA RQ.

**SARA 304 Extremely Hazardous Substances Reportable Quantity**

This material does not contain any components with a section 304 EHS RQ.

**SARA 302 Extremely Hazardous Substances Threshold Planning Quantity**

Components	CAS-No.	Component TPQ (lbs)
<b>SARA 311/312 Hazards</b>	: Combustible dust Acute toxicity (any route of exposure) Germ cell mutagenicity Reproductive toxicity	

**Clean Air Act**

This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

This product does not contain any hazardous air pollutants (HAP), as defined by the U.S. Clean Air Act Section 112 (40 CFR 61).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 112(r) for Accidental Release Prevention (40 CFR 68.130, Subpart F).

**KADCYLA Vials 160 mg**Version  
1.0Revision Date:  
07/28/2025Date of last issue: -  
Date of first issue: 07/28/2025

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 111 SOCMi Intermediate or Final VOC's (40 CFR 60.489).

**Clean Water Act**

This product does not contain any Hazardous Substances listed under the U.S. CleanWater Act, Section 311, Table 116.4A.

This product does not contain any Hazardous Chemicals listed under the U.S. CleanWater Act, Section 311, Table 117.3.

This product does not contain any toxic pollutants listed under the U.S. Clean Water Act Section 307

This product does not contain any priority pollutants related to the U.S. Clean Water Act

**US State Regulations****Massachusetts Right To Know**

.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl 57-50-1

**Pennsylvania Right To Know**

.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl 57-50-1  
Trastuzumab emtansine 1018448-65-1

**Maine Chemicals of High Concern****Vermont Chemicals of High Concern****Washington Chemicals of High Concern****California Permissible Exposure Limits for Chemical Contaminants**

.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl 57-50-1

**The ingredients of this product are reported in the following inventories:**


AIIC	:	Not in compliance with the inventory
DSL	:	This product contains the following components that are not on the Canadian DSL nor NDSL.  Trastuzumab emtansine
NZIoC	:	Not in compliance with the inventory
ENCS	:	Not in compliance with the inventory
ISHL	:	Not in compliance with the inventory
KECI	:	Not in compliance with the inventory
PICCS	:	Not in compliance with the inventory
IECSC	:	Not in compliance with the inventory
TCSI	:	Not in compliance with the inventory
TSCA	:	Product contains substance(s) not listed on TSCA inventory.
TECI	:	Not in compliance with the inventory

## KADCYLA Vials 160 mg

Version  
1.0Revision Date:  
07/28/2025Date of last issue: -  
Date of first issue: 07/28/2025**TSCA list**

No substances are subject to a Significant New Use Rule.

No substances are subject to TSCA 12(b) export notification requirements.

**SECTION 16. OTHER INFORMATION****Further information****NFPA 704:****HMIS® IV:**

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "\*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

**Full text of other abbreviations**

ACGIH	: USA. ACGIH Threshold Limit Values (TLV)
NIOSH REL	: USA. NIOSH Recommended Exposure Limits
OSHA P0	: USA. Table Z-1-A Limits for Air Contaminants (1989 vacated values)
OSHA Z-1	: USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants
ACGIH / TWA	: 8-hour, time-weighted average
NIOSH REL / TWA	: Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek
OSHA P0 / TWA	: 8-hour time weighted average
OSHA Z-1 / TWA	: 8-hour time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA -

**KADCYLA Vials 160 mg**Version  
1.0Revision Date:  
07/28/2025Date of last issue: -  
Date of first issue: 07/28/2025

International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Revision Date : 07/28/2025

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.

US / EN / 2404